A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance

A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance

Treatment options for advanced gallbladder cancer (GBC) are scarce and usually rely on cytotoxic chemotherapy, but the effectiveness of any regimen is limited and recurrence rates are high. Here, we investigated the molecular mechanisms of acquired resistance in GBC through the development and chara...

Full description

Bibliographic Details
Main Authors: Bizama, C. (Author), Buchegger, K. (Author), Espinoza, K. (Author), García, P. (Author), Ili, C. (Author), Leal, P. (Author), Obreque, J. (Author), Repetto, G. (Author), Roa, J.C (Author), Rosa, L. (Author), Suárez, F. (Author), Vergara-Gómez, L. (Author), Weber, H. (Author), Zhong, J. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2023
Subjects:
acquired drug resistance
carcinoma in situ
Carcinoma in Situ
Cell Line, Tumor
cytidine deaminase
Deoxycytidine
doxecitine
epithelial-to-mesenchymal transition
gallbladder cancer
Gallbladder Neoplasms
gallbladder tumor
gemcitabine
Gemcitabine
gene expression profiling
genetics
human
Humans
metabolism
proteomics
Proteomics
SILAC-based phosphoproteomics
tumor cell line
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items